Hospice providers are reimbursed a set rate per patient day no matter how little tx they deliver. What could go wrong when care for these vulnerable patients is managed by private equity firms and publicly traded companies that try to maximize short-term profits? bit.ly/3Z3Qm38 bit.ly/4eBZRw3

Hi! I’m a psychiatrist at Harvard and a clinical researcher with MAPS/Lykos building the evidence base for MDMA and psychedelic-assisted therapy, and training the next generation of psychedelic clinicians. I develop psychedelic curricula and teach residents about cross-cultural psychiatry. /